Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
PLoS One ; 12(11): e0187141, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29095875

RESUMEN

BACKGROUND: Few studies have examined the trajectories of symptom severity in first episode psychosis (FEP) and their impact on functioning. This study aimed to identify discrete trajectories of positive, negative and general psychopathological symptoms and functioning, determine predictors of the identified symptom trajectories and subsequently investigate the relationship between symptom and functioning trajectories over the 2-year follow-up period. METHODS: Data were extracted from the Singapore Early Psychosis Intervention Programme clinical database. Trajectories of the Positive and Negative Syndrome Scale and Global Assessment of Functioning (GAF) scale over the two-year follow up were modelled using latent class growth curve modelling. RESULTS: Two distinct trajectories (early response and stable trajectory and delayed response trajectory) for positive symptoms, four distinct trajectories (early response and stable trajectory, early response and relapse trajectory, slower response and no response trajectory and delayed response trajectory) for negative and general psychopathology symptoms and three distinct trajectories for functioning (high functioning trajectory, moderately stable functioning trajectory and deterioration in functioning trajectory) were identified in our sample. Compared to individuals in the early response and stable trajectory, those in the delayed response trajectory for positive and negative symptoms, early response and relapse for negative and general psychopathology symptoms and slower response and no response trajectories for general psychopathology symptoms were significantly associated with higher odds of having deterioration in functioning over time. Poor symptom trajectories were also significantly predicted by younger age, male gender, unemployed and economically inactive status, lower education, longer duration of untreated psychosis and diagnosis of schizophrenia spectrum and delusional disorders. CONCLUSIONS: The results confirm that the symptoms trajectories among patients with FEP are heterogeneous and suggest that a small group of patients may be at higher risk of deterioration in symptom severity and functioning over the 2-year follow-up.


Asunto(s)
Psicopatología , Trastornos Psicóticos/psicología , Adulto , Femenino , Estudios de Seguimiento , Humanos , Masculino , Singapur , Adulto Joven
3.
Early Interv Psychiatry ; 9(6): 516-22, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25203553

RESUMEN

AIM: Individuals with at-risk mental state (ARMS) experience subtle changes in thinking, behaviour and emotion before their first psychotic episode. Research has shown intervention provided during this period could delay, reduce, or even prevent the conversion to psychosis. In March 2008, the Support for Wellness Achievement Programme (SWAP) was launched for the assessment and treatment of patients with ARMS in Singapore. This paper examines the sociodemographic and clinical characteristics of patients at baseline. METHODS: In total, 384 patients were screened and 155 were accepted into the service. All patients were evaluated using the Comprehensive Assessment of At-Risk Mental State (CAARMS). Severity of psychopathology was assessed by Positive and Negative Syndrome Scale for Schizophrenia (PANSS) and levels of functioning were assessed using the Social and Occupational Functioning Assessment Scale (SOFAS). RESULTS: The mean age of the patients was 21.0 years (standard deviation (SD) = 3.5) and 69.7% were men, 42.6% had a relative with a mental health problem and 69.8% met the criterion solely for the attenuated symptoms group. The mean PANSS total score was 48.9 (SD = 10.8). There was also a high rate of comorbidity with 34.8% having depression and 20.0% had anxiety disorders. The mean baseline SOFAS score was 51.5 (SD = 9.8), indicating moderate impairment in their functioning. CONCLUSION: These preliminary findings have highlighted that our data are similar to other ARMS programmes, and in addition to the management of ARMS, there is a need to treat both the comorbidities and impairment in social occupational functioning.


Asunto(s)
Trastornos de Ansiedad/epidemiología , Depresión/epidemiología , Intervención Médica Temprana , Trastornos Psicóticos/epidemiología , Trastornos Psicóticos/terapia , Comorbilidad , Demografía , Femenino , Humanos , Masculino , Psicoterapia , Trastornos Psicóticos/diagnóstico , Trastornos Psicóticos/tratamiento farmacológico , Medición de Riesgo , Singapur/epidemiología , Adulto Joven
5.
AIDS Res Hum Retroviruses ; 26(8): 927-32, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20704495

RESUMEN

A survey for transmitted HIV drug resistance (HIVDR) was conducted according to WHO guidelines among clients newly diagnosed with HIV-1 infection at two voluntary counseling and testing centers (VCTC) in Mumbai. HIVDR testing was performed using the ViroSeq RT-PCR method (Abbott). Out of 50 successfully amplified and sequenced specimens, analysis of the first 34 consecutively collected specimens revealed no nucleoside reverse transcriptase inhibitor, nonnucleoside reverse transcriptase inhibitor, or protease inhibitor mutations from the 2007 WHO list of mutations for surveillance of transmitted HIVDR, indicating that the prevalence of transmitted HIVDR to all three drug classes was <5% among recently infected VCTC clients in Mumbai. The phylogenetic analysis revealed that all samples belonged to HIV-1 subtype C. Continued ART program monitoring and further evaluation of transmitted HIV drug resistance in coming years are essential in Mumbai as well as in other regions of the country in which ART is being scaled up rapidly.


Asunto(s)
Farmacorresistencia Viral Múltiple/genética , Infecciones por VIH/virología , VIH-1/genética , Sustitución de Aminoácidos , Farmacorresistencia Viral Múltiple/efectos de los fármacos , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Inhibidores de la Proteasa del VIH/uso terapéutico , VIH-1/efectos de los fármacos , Humanos , India/epidemiología , Masculino , Datos de Secuencia Molecular , Filogenia , ARN Viral/genética , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Análisis de Secuencia de ARN , Adulto Joven
6.
Chemotherapy ; 51(2-3): 116-9, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15886470

RESUMEN

BACKGROUND: Taxanes cause hypersensitivity reactions, averted by premedication with H1 blockers and high glucocorticoid (GC) doses. Prolonged weekly taxane administration may lead to GC toxicity. PURPOSE: To determine whether patients not hypersensitive to initial paclitaxel (PTX) infusion after high-dose GC premedication will tolerate subsequent, prolonged PTX treatment without GC prophylaxis. PATIENTS AND METHODS: In 115/122 breast cancer patients not hypersensitive to initial PTX treatment, 20 mg dexamethasone (DXM) doses were tapered by 2.0 mg/week, reaching 0 in those receiving 9 or more courses. After 4 PTX courses, diphenhydramine was administered orally, rather than intravenously. RESULTS: PTX was administered 143 times after 2.0-5.0 mg of DXM and 357 times without DXM. A total of 46 patients received 1-40 PTX courses without DXM. None of these 115 patients experienced hypersensitivity reactions. CONCLUSION: Patients unreactive to their first PTX infusions, after high-dose and tapering GC premedication, may not require GC prophylaxis for subsequent PTX therapy.


Asunto(s)
Antiinflamatorios/administración & dosificación , Antineoplásicos Fitogénicos/administración & dosificación , Dexametasona/administración & dosificación , Paclitaxel/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Antialérgicos/uso terapéutico , Antiinflamatorios/uso terapéutico , Antineoplásicos Fitogénicos/efectos adversos , Antineoplásicos Fitogénicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Dexametasona/uso terapéutico , Difenhidramina/uso terapéutico , Esquema de Medicación , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad a las Drogas/prevención & control , Quimioterapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Paclitaxel/efectos adversos , Paclitaxel/uso terapéutico , Estudios Prospectivos
7.
Leuk Lymphoma ; 44(4): 715-8, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12769351

RESUMEN

Myelofibrosis is most frequently associated with certain primary myeloproliferative disorders,but is rare in lymphoid neoplasms. We report the fourth case associated with T-cell lymphoma, involving bone marrow, lymph nodes and spleen. Marked extramedullary hematopoiesis was present. Myelofibrosis subsided completely with response to standard anti-lymphoma combination chemotherapy. Since lymphomatous splenic and bone marrow involvement was minimal in our patient, fibrotic bone marrows should be carefully evaluated for lymphoma.


Asunto(s)
Linfoma de Células T/complicaciones , Mielofibrosis Primaria/complicaciones , Biopsia , Médula Ósea/metabolismo , Femenino , Humanos , Ganglios Linfáticos/metabolismo , Linfoma de Células T/patología , Persona de Mediana Edad , Mielofibrosis Primaria/patología , Bazo/metabolismo
8.
Appl Immunohistochem Mol Morphol ; 10(2): 187-93, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12051640

RESUMEN

Preliminary retrospective chromosomal analysis was performed using fluorescence in situ hybridization (FISH) with alphoid DNA probes for chromosomes 1, 3, 6, 8, 12, 17, and X. Twenty-four epithelial ovarian tumors were examined in this pilot study, including 8 borderline (LMP) serous tumors, 9 serous carcinoma, and 7 mucinous carcinoma. Hybridization signals were counted to demonstrate the frequency of aneusomy, trace chromosomal progression, and identify the predominance of chromosome copy number abnormalities that are specific to a particular histotype. The preliminary results revealed almost an equal number of mean aneusomies in serous (58.13 +/- 13%) and mucinous (64.33 +/- 10%) carcinoma, both of which were slightly higher than borderline serous tumors (50.57 +/- 17%). Hyposomies 3 and X were significantly higher in mucinous than in serous ovarian carcinomas, and lowest in borderline serous tumors (P<0.05 and P<0.01). Signal losses were a more frequent abnormality in all three histologic subtypes. Mucinous carcinomas showed a loss of chromosomes 8 (45.00 +/- 28%) and 3 (43.14 +/- 16%), in addition to a loss of chromosome X (56.29 +/- 12%). Serous carcinomas showed a gain of chromosome 1 (39.44 +/- 32%), followed by losses of chromosomes 6 (37.00 +/- 20%), 17 (36.44 +/- 19%), and 8 (36.89 +/- 19%). In borderline serous tumors, the most frequent findings were losses of chromosomes 6 (38.00 +/- 17%), 12 (36.88 +/- 17%), and 3 (36.13 +/- 21%). However, further research is necessary to substantiate these preliminary results and elucidate their clinical significance. A brief review of the literature pertaining to interphase cytogenetics in ovarian epithelial tumors is discussed also.


Asunto(s)
Aberraciones Cromosómicas , Hibridación Fluorescente in Situ/métodos , Neoplasias Ováricas/genética , Femenino , Humanos , Neoplasias Ováricas/patología , Proyectos Piloto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...